Savara Pharmaceuticals Adds $10M For Inhaled Antibiotic

Austin-based Savara Pharmaceuticals announced this morning that it has raised $10M in a bridge financing round, to go towards its inhaled antibiotics. According to the company, the funding came from its previous investors, plus un-named investors include boutique investment funds and family offices. Savara Pharmaceuticals said the funding goes towards a study of its lead compound, AeroVance, which is being targeted at treating MRSA lung infections in people with cystic fibrosis. The company said results of that study are expected in the first quarter of 2015. More information »